eldora-ellison
28 October 2020BiotechnologySarah Morgan

LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101

Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler  Goldstein & Fox.

Yesterday, October 27, Ellison provided her thoughts on a range of topics, including life sciences trends and diversity and inclusion in the legal profession, during an LSPN Connect interview.

Ellison, who serves as a director in Sterne Kessler’s biotechnology and chemical, and trial and appellate practice groups, is also the lead patent strategist on CRISPR-Cas9 matters for the University of California.

Earlier this month, French microbiologist Emmanuelle Charpentier and US biochemist Jennifer Doudna (professor of chemistry at the University of California, Berkeley) jointly won the Nobel Prize in chemistry for their seminal work CRISPR.

While Ellison couldn’t talk about the long-running dispute between the university and the Broad Institute of MIT and Harvard University, she did speak more generally about the landscape.

“When our firm was first brought in, the University of California was still trying to develop [the technology] and obtain patents. Now it has more than 30 issued patents,” said Ellison.

She added: “The patents involved in the ongoing interference cover basic platform technology. As more and more entities undertake more research on the technology, there will be refinements, just like any other field.”

Ellison predicted that we’re likely to see more innovations being developed and more patents being granted. Entities interested in working on the technology will need to be careful to navigate the IP in this growing and complex field.

Trends on the horizon

Looking ahead, Ellison hopes “legislators can reform section 101 so we can provide adequate patent protection in the diagnostics space”.

Section 101 sets out that “any new and useful process, machine, manufacture, or composition of matter” is patent-eligible, but judicial exceptions prohibit patent claims directed to a law of nature, a natural phenomenon or an abstract idea.

Ellison added: “Like with anything in the patent system, we want to keep the scientists motivated and we want to promote innovation like the patent system is designed to do. Unfortunately, section 101 is not quite living up to the job it needs to do.”

On the PTAB front, Ellison notes that a lot of discretionary denials are being seen, particularly in cases where the same arguments have been made previously.

“Lately, we’ve seen the board deny trial when district court litigation is so far advanced that in the PTAB’s mind, it may not be efficient for the board to institute trial,” she explained.

From Ellison’s perspective, one of the most important things for stakeholders is having some degree of predictability.

The American Invents Act was enacted in an effort to give stakeholders the ability to challenge patents outside of district court litigation, said Ellison.

“If we have some sense of predictability around whether a trial will be instituted, then companies can make their business decisions as to whether it makes sense for them to move forward with a given proceeding,” she added.

Earlier this month, the US Patent and Trademark Office published a request for comments on the board’s discretion to institute trials.

COVID-19 and diversity

Finally, Ellison also described the impact the COVID-19 pandemic is having on Sterne Kessler and the level of diversity and inclusion in the legal profession.

Applauding the firm’s IT team, she said that Sterne Kessler was able to transition to working from home pretty seamlessly and quickly.

“This makes us think about life in the future post-COVID and wonder what that’s going to look like. Now that we see that we really can have the entire firm working remotely, how much of the firm do we need to have work on site going forward?

“I think there are some whole departments that we think can work remotely indefinitely,” she said. “With some of our back-office operations, we don’t see the need for them to be on site.”

On diversity and inclusion, Ellison noted that she’s seen some positive responses from the legal industry to the Black Lives Matter movement.

“It’s refreshing and it's unfortunate that it’s taken so long, but there are silver linings that probably come out of every situation and I try to find them,” she said. “A number of companies and institutions have made an active effort to insist upon diversity in their choice of counsel.”

Ellison has seen some specific outreaches by entities trying to change the way they’ve been doing things, and not go with default choices they’ve made in the past.

“The fact that there’s more discussion about it and more efforts to hire, retain and train people is a step in the right direction for everyone’s benefit,” she concluded.

LSPN Connect is the membership programme for the Life Sciences—to watch on this session and for more information on joining, visit www.lspnconnect.com

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Today’s top stories

Five minutes with… Fred Felman, Appdetex

USPTO records 100% surge in AI patents since 2002

Playboy sues over bunny Halloween costumes


More on this story

Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Genetics
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
Americas
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.

More on this story

Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Genetics
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
Americas
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.